Subjects: INFLAMAÇÃO, CÉLULAS ESTROMAIS, ENFISEMA PULMONAR
ABNT
STOLK, J. et al. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM, v. 109, n. Ja 2016, p. 331-336, 2016Tradução . . Disponível em: https://doi.org/10.1093/qjmed/hcw001. Acesso em: 04 nov. 2024.APA
Stolk, J., Broekman, W., Mauad, T., Zwaginga, J. J., Roelofs, H., Fibbe, W. E., et al. (2016). A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM, 109( Ja 2016), 331-336. doi:10.1093/qjmed/hcw001NLM
Stolk J, Broekman W, Mauad T, Zwaginga JJ, Roelofs H, Fibbe WE, Oostendorp J, Bajema I, Versteegh MIM, Taube C, Hiemstra PS. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema [Internet]. QJM. 2016 ; 109( Ja 2016): 331-336.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1093/qjmed/hcw001Vancouver
Stolk J, Broekman W, Mauad T, Zwaginga JJ, Roelofs H, Fibbe WE, Oostendorp J, Bajema I, Versteegh MIM, Taube C, Hiemstra PS. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema [Internet]. QJM. 2016 ; 109( Ja 2016): 331-336.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1093/qjmed/hcw001